文献速递区域麻醉与超声疼痛医学

术前地塞米松用于全膝关节置换术后镇痛:一项随机对照试验

Preoperative dexamethasone for pain relief after total knee arthroplasty: A randomised controlled trial.
PubMed 文献 · Eur J Anaesthesiol · 2020-01-01

主要结局为术后疼痛评分。结果显示,与安慰剂相比,地塞米松16 mg可显著减轻术后第3天最大主动屈曲时的疼痛,减少阿片类药物消耗,增强股四头肌肌力,改善活动能力及恢复质量,但未发现长期疼痛和膝关节功能的改善。

要点

  • 术前地塞米松16 mg可减轻全膝关节置换术后疼痛并减少阿片消耗。
  • 地塞米松16 mg组术后股四头肌肌力更强、步行距离更远、恢复质量更高。
  • 未观察到地塞米松对术后3、6、12个月慢性疼痛或膝关节功能的显著改善。

核心结论

  • 术前给予地塞米松16 mg可改善全膝关节置换术后镇痛、减少阿片消耗、增强股四头肌肌力、促进活动并提高恢复质量,但无长期疼痛与功能改善。

主要发现

  • 与安慰剂相比,D16组术后第3天最大主动屈曲时疼痛评分显著降低[-1.3(95%CI,-2.2至-0.31),P=0.005]。
  • 疼痛评分与地塞米松剂量间存在显著剂量依赖趋势(P=0.002)。
  • 与安慰剂相比,D16组阿片类药物消耗显著减少[-6.4 mg(95%CI,-11.6至-1.2),P=0.025]。
  • D16组术后前三天股四头肌肌力更强(所有P<0.05),术后第1天步行距离更长[7.8 m(95%CI,0.85至14.7),P=0.023]。
  • D16组术后前两日步行辅助更少(所有P<0.029),术后第1天恢复质量评分更优(P=0.018)。

关键数值与推荐

  • 术前分别给予地塞米松8 mg(D8组)、16 mg(D16组)或安慰剂(0.9%氯化钠,P组)。
  • 主要结局为术后疼痛评分;次要结局包括阿片消耗、膝关节物理参数及地塞米松副作用。
  • 上述所有参数与地塞米松剂量间均存在显著剂量依赖趋势(所有P<0.05)。
  • 术后3、6、12个月慢性疼痛发生率或膝关节功能无显著差异。

临床怎么用

  • 对于全膝关节置换术患者,可考虑术前给予地塞米松16 mg以改善术后短期镇痛、减少阿片用量并促进早期活动。
  • 需注意地塞米松对长期疼痛和膝关节功能无明显改善作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Corticosteroids can reduce pain but the optimal dose and safety profiles are still uncertain. OBJECTIVE: This study aimed to evaluate two different doses of dexamethasone for pain management and their side effects after total knee arthroplasty. DESIGN: A prospective randomised, controlled trial. SETTING: A tertiary teaching hospital in Hong Kong. PATIENTS: One hundred and forty-six patients were randomly allocated to one of three study groups. INTERVENTIONS: Before operation, patients in group D8, D16 and P received dexamethasone 8 mg, dexamethasone 16 mg and placebo (0.9% saline), respectively. MAIN OUTCOME MEASURES: The primary outcome was postoperative pain score. Secondary outcomes were opioid consumption, physical parameters of the knees and side effects of dexamethasone. RESULTS: Compared with placebo, group D16 patients had significantly less pain during maximal active flexion on postoperative day 3 [-1.3 (95% CI, -2.2 to -0.31), P = 0.005]. There was also a significant dose-dependent trend between pain scores and dexamethasone dose (P = 0.002). Compared with placebo, patients in group D16 consumed significantly less opioid [-6.4 mg (95% CI, -11.6 to -1.2), P = 0.025] and had stronger quadriceps power on the first three postoperative days (all P < 0.05). They also had significantly longer walking distance on postoperative day 1 [7.8 m ([95% CI, 0.85 to 14.7), P = 0.023] with less assistance during walking on the first two postoperative days (all P < 0.029) and significantly better quality-of-recovery scores on postoperative day 1 (P = 0.018). There were significant dose-dependent trends between all the above parameters and dexamethasone dose (all P < 0.05). No significant differences were found in the incidence of chronic pain or knee function 3, 6 and 12 months postoperatively. CONCLUSION: Dexamethasone 16 mg given before total knee arthroplasty led to a reduction in postoperative pain, less opioid consumption, stronger quadriceps muscle power, better mobilisation and better overall quality-of-recovery after operation. No long-term improvement in reduction in pain and function of the knee was found. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02767882.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Chan TCW, Cheung CW, Wong SSC, et al. Preoperative dexamethasone for pain relief after total knee arthroplasty: A randomised controlled trial. Eur J Anaesthesiol. 2020. PMID: 33105245. doi:10.1097/EJA.0000000000001372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。